Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 5,521 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo once daily Clear all

Conditions: Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions: LHP588, Placebo Drug; Drug
Lead sponsor: Lighthouse Pharmaceuticals, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more

Conditions: Hepatitis C Virus
Interventions: Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more

Conditions: Rheumatoid Arthritis
Interventions: PTC844, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Chandler, Arizona • Flagstaff, Arizona • Phoenix, Arizona + 10 more

Conditions: Myocardial Ischemia
Interventions: Dapagliflozin 10mg Tab, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy Volunteer
Interventions: aleglitazar, aspirin, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Estriol, Placebo, Copaxone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Overactive Bladder
Interventions: Darifenacin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 65 Years and older
Enrollment: 400 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Diseases, Interstitial Cystitis
Interventions: Amitriptyline, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Stanford, California • Maywood, Illinois • Iowa City, Iowa + 6 more

Conditions: Resistant Hypertension
Interventions: Placebo, TBC3711; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 9 more

Conditions: Asthma
Interventions: QAW039, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Guanfacine, Methylphenidate (MPH); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 7 Years to 14 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tophaceous Gout
Interventions: Lesinurad, Placebo, Febuxostat; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 99
States / cities: Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 85 more

Conditions: Acute Coronary Syndrome
Interventions: A-002, varespladib methyl, Placebo; Drug
Lead sponsor: Anthera Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 5,189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 83
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more

Conditions: Cachexia
Interventions: GSK2881078, Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Conditions: Type 2 Diabetes Mellitus
Interventions: Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 72
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 20
States / cities: Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more

Conditions: Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity
Interventions: Vitamin D ergocalciferol, Probenecid, Allopurinol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: caffeine and ephedrine, Leptin A, caffeine, ephedrine, and leptin A; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Sleep Disorder
Interventions: ABT-652, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Phoenix, Arizona • Glendale, California • San Diego, California + 2 more

Conditions: Non-small Cell Lung Cancer, Squamous Lung Dysplasia
Interventions: placebo, inositol; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 45 Years to 79 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Scottsdale, Arizona • Rochester, Minnesota • Albuquerque, New Mexico

Conditions: Chronic Migraine
Interventions: Atogepant, Placebo for Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 32
States / cities: Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more

Conditions: Depression
Interventions: Duloxetine, Placebo matching with BMS-820836, BMS-820836, Placebo matching with Duloxetine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 55
States / cities: Little Rock, Arkansas • Arcadia, California • Encino, California + 42 more

Conditions: Insomnia
Interventions: Ramelteon, Usual Care; Drug · Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Study of PTC844 in Participants With Active Rheumatoid Arthritis

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Ramelteon for Complex Insomnia in Veterans With PTSD